RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

Enemem, making the best out of Cor doing "nothing"

Selling Cor 2009 offset some cap gains 2009.

Despite low vol, 2010 Cor purchase, 30+ days later, is looking good, at least on paper this year with 50%+ return.

Despite all this, ampakines have not provided or preserved analgesia from Cor investment................so far?